Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
PD-1 Blockade
100%
Refractory Lymphoma
100%
Relapsed or Refractory
100%
Confidence Interval
80%
Graft-versus-host Disease (GvHD)
60%
Hematopoietic Stem Cell Transplant
60%
Lymphoma
40%
Programmed Death-ligand 1 (PD-L1)
40%
T Cells
20%
CD8+ T Cells
20%
Previously Treated
20%
Prior Treatment
20%
Retrospective Analysis
20%
Sinusoidal Obstruction Syndrome
20%
Non-relapse Mortality
20%
Anti-PD-1 Monoclonal Antibody
20%
Regulatory T (Treg) Cells
20%
Low Dose Rate
20%
Cumulative Incidence
20%
Median Time
20%
Progression-free Survival
20%
Immune Toxicity
20%
Non-infectious
20%
Treatment-related Mortality
20%
Annualized Relapse Rate
20%
Peripheral Blood Lymphocyte Subsets
20%
Immune Alterations
20%
Febrile Syndrome
20%
PD-1 Inhibitor
20%
Anti-programmed Cell Death Protein 1
20%
CD4 T Cells
20%
Prolonged Course
20%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
100%
Syndrome
50%
Chronic Graft Versus Host Disease
50%
CD8 Antigen
50%
Programmed Death 1 Receptor
50%
Progression Free Survival
50%
Survival Rate
50%
Immunotoxicity
50%
Liver Venoocclusive Disease
50%
Monoclonal Antibody
50%
Medicine and Dentistry
Hematopoietic Stem Cell Transplantation
100%
Acute Graft Versus Host Disease
40%
Cumulative Incidence
40%
T Cell
20%
T-Helper Cell
20%
Cytotoxic T-Cell
20%
Regulatory T Cell
20%
Chronic Graft Versus Host Disease
20%
Liver Venoocclusive Disease
20%
Progression Free Survival
20%
Survival Rate
20%
Lymphocyte Subpopulation
20%
Programmed Death 1 Receptor
20%
Immunotoxicity
20%
Monoclonal Antibody
20%
Immunology and Microbiology
Hematopoietic Stem Cell Transplantation
100%
Acute Graft Versus Host Disease
40%
Regulatory T Cell
20%
Cytotoxic T-Cell
20%
T-Helper Cell
20%
Monoclonal Antibody
20%
Chronic Graft Versus Host Disease
20%
Programmed Death 1 Receptor
20%
Survival Rate
20%
Lymphocyte Subpopulation
20%
Progression Free Survival
20%
T Cell
20%